28 studies found for:    Open Studies | "Polymyositis"
Show Display Options
Rank Status Study
21 Recruiting Safety and Efficacy of BAF312 in Dermatomyositis
Condition: Active Dermatomyositis
Interventions: Drug: BAF312 0.5 mg;   Drug: BAF312 2 mg;   Drug: BAF312 10 mg;   Drug: Placebo to BAF312
22 Not yet recruiting Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders
Conditions: Osteoporosis;   Juvenile Rheumatoid Arthritis;   Dermatomyositis;   Polyarthritis;   Systemic Lupus Erythematosis;   Vasculitis;   Glucocorticoid-induced Osteoporosis
Intervention: Drug: denosumab
23 Available Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes
Conditions: Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE);   Juvenile Dermatomyositis (JDM);   Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI)
Intervention: Drug: Baricitinib
24 Unknown  Evaluating N-Acetylcysteine in CTD-ILD Treatment
Conditions: Interstitial Lung Disease;   Connective Tissue Disease
Intervention: Drug: N-Acetylcysteine
25 Recruiting Belimumab in Myositis
Condition: Myositis
Intervention: Drug: Belimumab + standard of care (randomized phase)
26 Unknown  A Case-control Study to Assess Risk of Coronary Heart Disease in Idiopathic Inflammatory Myopathy
Condition: Idiopathic Inflammatory Myopathy
Intervention:
27 Unknown  Detection of Pompe Disease in Adult Patients With Myopathies of Uncertain Origin or With Asymptomatic Hyper-CK-emia
Condition: Pompe Disease
Intervention:
28 Recruiting Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD
Conditions: Interstitial Lung Disease;   Scleroderma;   Idiopathic Inflammatory Myositis;   Mixed Connective Tissue Disease
Interventions: Drug: Rituximab;   Drug: Cyclophosphamide

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-28) Next Page   
Indicates status has not been verified in more than two years